Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeting CEBPA to restore cellular identity and tissue homeostasis in pulmonary fibrosis
Qi Tan, Jack H. Wellmerling, Shengren Song, Sara R. Dresler, Jeffrey A. Meridew, Kyoung M. Choi, Yong Li, Y.S. Prakash, Daniel J. Tschumperlin
Qi Tan, Jack H. Wellmerling, Shengren Song, Sara R. Dresler, Jeffrey A. Meridew, Kyoung M. Choi, Yong Li, Y.S. Prakash, Daniel J. Tschumperlin
View: Text | PDF
Research Article Pulmonology Stem cells

Targeting CEBPA to restore cellular identity and tissue homeostasis in pulmonary fibrosis

  • Text
  • PDF
Abstract

Fibrosis in the lung is thought to be driven by epithelial cell dysfunction and aberrant cell-cell interactions. Unveiling the molecular mechanisms of cellular plasticity and cell-cell interactions is imperative to elucidating lung regenerative capacity and aberrant repair in pulmonary fibrosis. By mining publicly available RNA-Seq data sets, we identified loss of CCAAT enhancer-binding protein alpha (CEBPA) as a candidate contributor to idiopathic pulmonary fibrosis (IPF). We used conditional KO mice, scRNA-Seq, lung organoids, small-molecule inhibition, and potentially novel gene manipulation methods to investigate the role of CEBPA in lung fibrosis and repair. Long-term (6 months or more) of Cebpa loss in AT2 cells caused spontaneous fibrosis and increased susceptibility to bleomycin-induced fibrosis. Cebpa knockout (KO) in these mice significantly decreased AT2 cell numbers in the lung and reduced expression of surfactant homeostasis genes, while increasing inflammatory cell recruitment as well as upregulating S100a8/a9 in AT2 cells. In vivo treatment with an S100A8/A9 inhibitor alleviated experimental lung fibrosis. Restoring CEBPA expression in lung organoids ex vivo and during experimental lung fibrosis in vivo rescued CEBPA deficiency–mediated phenotypes. Our study establishes a direct mechanistic link between CEBPA repression, impaired AT2 cell identity, disrupted tissue homeostasis, and lung fibrosis.

Authors

Qi Tan, Jack H. Wellmerling, Shengren Song, Sara R. Dresler, Jeffrey A. Meridew, Kyoung M. Choi, Yong Li, Y.S. Prakash, Daniel J. Tschumperlin

×

Figure 2

Loss of Cebpa in AT2 cells promotes lung fibrotic response, impairs fibrosis resolution and lung repair.

Options: View larger image (or click on image) Download as PowerPoint
Loss of Cebpa in AT2 cells promotes lung fibrotic response, impairs fibr...
(A) Schematic showing tamoxifen treatment and analysis timeline. (B–D) Representative immunostaining images (n = 3) of Cebpa expression, qPCR of Cebpa transcripts, and representative Western blot (n = 3) showing Cebpa expression from CebpaΔSftpc and Cebpafl/fl mice lungs, 4 weeks after tamoxifen treatment. Scale bar: 50 μM. (E and F) Weight change of CebpaΔSftpc (n = 14) and Cebpafl/fl (n = 12) mice, and survival curve of CebpaΔSftpc (n = 18) and Cebpafl/fl (n = 10) mice after first tamoxifen treatment, over a 26-week period. (G) Hydroxyproline assay showing collagen deposition from CebpaΔSftpc (n = 11) and Cebpafl/fl (n = 9) mice lungs 26 weeks after first tamoxifen treatment. (H and I) Representative Western blot and their quantification show fibronectin and α-SMA expression from CebpaΔSftpc and Cebpafl/fl mice lungs 26 weeks after tamoxifen treatment. (J) qPCR for profibrotic gene transcripts from CebpaΔSftpc and Cebpafl/fl mice lungs 26 weeks after first tamoxifen treatment. (K) Representative H&E staining showing lung sections from CebpaΔSftpc (n = 3) and Cebpafl/fl (n = 3) mice 26 weeks after first tamoxifen treatment. Scale bar: 100 μM. (L) Flow cytometry analysis of CD326+ cells from CebpaΔSftpc (n = 7) and Cebpafl/fl (n = 7) mice lungs 26 weeks after first tamoxifen treatment. (M) Schematic showing timeline for bleomycin treatment, tamoxifen treatment, and analysis. (N) Hydroxyproline assay from CebpaΔSftpc and Cebpafl/fl mice lungs at 4 and 5 weeks after bleomycin injury. (O) Hydroxyproline assay from CebpaΔSftpc and Cebpafl/fl mice lungs at 12 weeks after bleomycin injury. (P) Representative H&E staining showing lung sections from CebpaΔSftpc (n = 3) and Cebpafl/fl (n = 3) mice at 12 weeks after bleomycin injury. Scale bar: 200 μM. (Q and R) Survival curve and weight change of CebpaΔSftpc (n = 10) and Cebpafl/fl (n = 7) mice over a 12-week postbleomycin injury period. Data were analyzed using a Mann-Whitney U test. *P < 0.05, **P < 0.01, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts